Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accumulated Depreciation & Amortization (2021 - 2025)

Kiniksa Pharmaceuticals International's Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 11.75% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $7.2 million, down 11.75%, while the annual FY2025 figure was $7.2 million, 11.75% down from the prior year.
  • Accumulated Depreciation & Amortization reached $7.2 million in Q4 2025 per KNSA's latest filing, down from $7.8 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $8.2 million in Q4 2024 to a low of $5.0 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $7.1 million, with a median of $7.3 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: grew 24.98% in 2022, then dropped 11.75% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $5.9 million in 2021, then grew by 15.96% to $6.9 million in 2022, then increased by 13.5% to $7.8 million in 2023, then grew by 5.24% to $8.2 million in 2024, then decreased by 11.75% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Accumulated Depreciation & Amortization are $7.2 million (Q4 2025), $7.8 million (Q3 2025), and $7.8 million (Q2 2025).